Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition

Combination therapy targeting the PD-1/PD-L1 and TIGIT pathways has been explored to enhance the efficacy of current immunotherapies. In this study, we investigated strategies to further potentiate the co-blockade of PD-L1 and TIGIT for cancer immunotherapy. Firstly, we demonstrated that the bispeci...

Descripció completa

Dades bibliogràfiques

Autors principals:	Xi Zhu, Xiaopei Cui, Haijia Yu, Jingen Xu, Xiaofang Chen, Xiaochen Ren, Xiaoyue Wei, Shi Chen, Yangtin Wang, Liyang Fei, Bin Xie, Mingwei Li, Xue Li, Huifeng Jia, Yujie Feng, Simin Xia, Li Chen, Yong Cheng, Lei Zhang, Haidong Li, Xiangyang Zhu, Yifan Zhan
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2026-01-01
Col·lecció:	Frontiers in Immunology
Matèries:	bispecific antibody combination (combined) therapy PD-(L)1 TIGIT TME (tumor microenvironment) Treg - regulatory T cell
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1746155/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!